Hao Xiujuan, Huang Yan, Qiu Ming, Yin Chunlin, Ren Huiming, Gan Hongjie, Li Huijun, Zhou Yaxia, Xia Jiazhi, Li Wenting, Guo Lijuan, Angres Isaac A
Arthus Biosystems, 2600 Hilltop Dr., Richmond, CA, 94806, USA.
Department of Infectious Diseases, Xiangya Hospital, Central South University Hospital, Changsha, China.
BMC Res Notes. 2016 Nov 28;9(1):498. doi: 10.1186/s13104-016-2296-8.
S-Adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are relevant to a variety of diseases. Previous reports that quantified SAM and SAH were based on HPLC or LC-MS/MS. No antibody against SAM has been generated, and the antibody against SAH cannot be used with blood samples. Immunoassays have not been used to measure SAM and SAH. In this study, ELISA was used to measure blood SAM and SAH levels.
Specific antibodies against SAM were produced for the first time using a stable analog as the antigen. The monoclonal antibodies against SAM and SAH were characterized. No cross-reactivity was detected for the analyzed analogs. For the anti-SAM antibodies, the ELISA sensitivity was ~2 nM, and the affinity was 7.29 × 10 L/mol. For the anti-SAH antibodies, the sensitivity was ~15 nM, and the affinity was 2.79 × 10 L/mol. Using high-quality antibodies against SAM and SAH, immunoassays for the detection of SAM and SAH levels in blood and tissue samples were developed. Clinical investigations using immunoassays to measure SAM, SAH and the methylation index (MI) in normal and diseased samples indicated that (1) the SAM level is age and gender dependent; (2) the SAM level is associated with the severity of liver diseases, inflammatory reactions and other diseases; and (3) the methylation index (MI) is significantly reduced in many diseases and may serve as a screening biomarker to identify potentially unfavorable health conditions.
It is possible to generate antibodies against active small biomolecules with weak immunogenicity, such as SAM and SAH, using traditional hybridoma technology. The antigens and antibodies described here will contribute to the development of immunoassays to measure SAM, SAH and related molecules. These assays enable the MI to be measured specifically, accurately, easily and quickly without costly equipment. This preliminary study indicates that the MI could be an effective indicator of general health, except under conditions that may alter the value of the MI, such as special diets and medications.
S-腺苷甲硫氨酸(SAM)和S-腺苷高半胱氨酸(SAH)与多种疾病相关。先前对SAM和SAH进行定量的报告是基于高效液相色谱法(HPLC)或液相色谱-串联质谱法(LC-MS/MS)。尚未产生针对SAM的抗体,且针对SAH的抗体不能用于血液样本。免疫测定法尚未用于测量SAM和SAH。在本研究中,采用酶联免疫吸附测定法(ELISA)来测量血液中SAM和SAH的水平。
首次使用稳定类似物作为抗原制备了针对SAM的特异性抗体。对针对SAM和SAH的单克隆抗体进行了表征。在所分析的类似物中未检测到交叉反应。对于抗SAM抗体,ELISA灵敏度约为2 nM,亲和力为7.29×10 L/mol。对于抗SAH抗体,灵敏度约为15 nM,亲和力为2.79×10 L/mol。利用针对SAM和SAH的高质量抗体,开发了用于检测血液和组织样本中SAM和SAH水平的免疫测定法。使用免疫测定法对正常和患病样本中的SAM、SAH和甲基化指数(MI)进行临床研究表明:(1)SAM水平与年龄和性别有关;(2)SAM水平与肝脏疾病、炎症反应及其他疾病的严重程度相关;(3)甲基化指数(MI)在许多疾病中显著降低,可能作为一种筛查生物标志物来识别潜在的不良健康状况。
使用传统杂交瘤技术能够产生针对免疫原性较弱的活性小生物分子(如SAM和SAH)的抗体。此处描述的抗原和抗体将有助于开发用于测量SAM, SAH及相关分子的免疫测定法。这些测定法能够在无需昂贵设备的情况下,特异性、准确、简便且快速地测量MI。这项初步研究表明,除了可能改变MI值的情况(如特殊饮食和药物)外,MI可能是总体健康状况的有效指标。